Quantcast

Latest Ciprofloxacin Stories

2008-11-12 18:00:21

Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2008. Revenue for the third quarter was $197,000, compared with revenue of $230,000 for the third quarter of 2007. Revenue in the third quarter of 2008 was primarily the result of expense reimbursement from a third party for the evaluation of the delivery of certain compounds using the AERx(R) delivery system. Total operating expenses for the...

2008-11-12 12:00:31

Novexel, a specialty pharmaceutical company, has initiated Phase II clinical trial of its advanced injectable antibacterial, which combines the company's broad spectrum beta-lactamase inhibitor, NXL104, with cephalosporin antibiotic, ceftazidime. This Phase II trial is a prospective, multicenter, investigator-blinded, randomized study which is designed to evaluate the efficacy, safety, and tolerability of NXL104/ceftazidime versus imipenem cilastatin (Primaxin or Tienam, Merck & Co) in...

2008-11-05 18:00:22

SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL(R) (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers). In an Approvable Letter received on April 6, 2006, the FDA requested additional data with respect to chemistry, manufacturing, and controls (CMC). SALVAT expects the FDA to classify the complete response as a Class 2 resubmission, under which the FDA will seek to complete its review of the resubmission within 180 days from the...

2008-10-27 12:00:10

WASHINGTON, Oct. 27 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced new study results that demonstrate doripenem (DORIBAX(TM), doripenem for injection), a carbapenem antibiotic, was found to be more potent in vitro against certain strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases (ESBLs) than other commonly used carbapenems. Enterobacteriaceae is a large group of bacteria that can cause...

2008-10-23 06:00:11

Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 2 study of inhaled liposomal ciprofloxacin (ARD-3100) in cystic fibrosis (CF) patients at the 22nd Annual North American Cystic Fibrosis (NACF) conference in Orlando, Florida. Completed in June 2008, the study was an open-label, two week efficacy and safety trial of once daily inhaled liposomal ciprofloxacin in 22 CF patients conducted at leading CF centers in Australia and New Zealand....

2008-10-16 06:00:31

Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, October 30, 2008. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results and to provide an update and future outlook on company events. Interested parties can access the live and archived broadcast of the call at www.depomedinc.com. About Depomed Depomed, Inc. is a specialty...

2008-10-15 03:00:22

Aradigm has completed enrollment in its Phase II clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis. The study was initiated in July 2008 in bronchiectasis centers in the UK and enrolled a total of 36 patients as planned. The subjects were randomized to two different dose levels of once-daily inhaled liposomal ciprofloxacin in a parallel design for a treatment period of 28 consecutive days. The primary efficacy endpoint in the...

2008-10-14 06:00:16

Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis. The study was initiated in July 2008 in leading bronchiectasis centers in the United Kingdom and enrolled a total of 36 patients as planned. The subjects were randomized to two different dose levels of once-daily inhaled liposomal ciprofloxacin in a parallel design for a...

2008-09-18 15:00:38

Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be held in New York City. Interested parties can access a live, or archived, webcast of the presentation on the company's website at www.depomedinc.com. About Depomed Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and...

2008-08-30 09:00:20

By Jarzembowski, Jason A Young, Michael B * Context.-Nontuberculous mycobacteria include numerous acid- fast bacilli species, many of which have only recently been recognized as pathogenic. The diagnosis of mycobacterial disease is based on a combination of clinical features, microbiologic data, radiographic findings, and histopathologic studies. Objective.-To provide an overview of the clinical and pathologic aspects of nontuberculous mycobacteria infection, including diagnostic laboratory...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.